Relation of kynurenine/tryptophan with immune and inflammatory markers in coronary artery disease

Clinical Laboratory

Volumn 60, Issue 3, 2014, Pages 391-396

  Ozkan, Yesim ^a   Sukuroglu, Murat Kadir ^a   Tulmac, Murat ^b   Kisa, Ucler ^b   Simsek, Bolkan ^a  

^a GAZI UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Indolamine 2,3 dioxygenase; Kynurenine; Neopterin; Tryptophan

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KYNURENINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NEOPTERIN; TRIACYLGLYCEROL; TRYPTOPHAN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME DEGRADATION; FEMALE; GENSINI SCORE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KYNURENINE; MALE; MIDDLE AGED; NEOPTERIN; PEROXIDASE; SPECTROPHOTOMETRY, ULTRAVIOLET; TRYPTOPHAN;

EID: 84896474886     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.121204     Document Type: Article

References (42)

1. Geng YJ, Jonasson L. Linking immunity to atherosclerosis: Implication for vascular pharmacology - A tribute to Göran K. Hansson. Vase Pharmacol 2012;56:29-33.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43. (Pubitemid 34212626)
3. Chen Y, Guillemin GJ. Kynurenine Pathway Metabolites in Humans: Disease and Healthy States. Int J Tryptophan Res 2009;2:1-19.
4. Xu H, Zhang GX, Ciric B, Rostami A. IDO: A double-edged sword for TH1/TH2 regulation. Immunol Lett 2008;121:1-6.
5. Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993;101:1-6. (Pubitemid 23179069)
6. Sheldon J, Riches PG, Soni N, et al. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clin Chem 1991;37:2038-42. (Pubitemid 21925897)
7. Ozkan Y, Mete G, Sepici-Dincel A, Sepici V, Simsek B. Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients. Clin Rheumatol 2012;31:29-34.
8. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Therap 2001;26:319-29. (Pubitemid 32989554)
9. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett 2010;287:13-22.
10. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74. (Pubitemid 39336293)
11. Sakash JB, Bryne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: Implications for persistent Chlamydophila pneumonia infection. Infect Immun 2002;70:3959-61. (Pubitemid 34666040)
12. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003;33:550-54. (Pubitemid 36783213)
13. Pertovaara M, Raitala A, Juonala M, et al. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007;148:106-11. (Pubitemid 46364993)
14. Gensini GG. More meaningful scoring system for determining the severity of coronary artery disease. Am J Cardiol 1983;51:604-6.
15. Xiaoqing Z, Yun H, Min D. Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. J Chromatogr B 2009;887:1678-82.
16. Libby R. Inflammation in atherosclerosis. Nature 2002;420:868-74.
17. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46.
18. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primaryly under control of interferon gamma. J Exp Med 1984;160:310-6. (Pubitemid 14089799)
19. Wirleitner B, Reider D, Ebner S, et al. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol 2002;72:1148-53. (Pubitemid 36008885)
20. Weiss G, Willeit J, Kiechl S, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994;106:263-71.
21. Schumacher M, Halwachs G, Tatzber F, et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997;30:703-7. (Pubitemid 27397650)
22. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747-53. (Pubitemid 39299216)
23. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005;26:457-63.
24. Murr C, Winklhofer-Roob BM, Schroecksnadel K, et al. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009;202:543-9.
25. Sugioka K, Naruko T, Hozumi T, et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis 2010;208:524-30.
26. Fuchs D, Avanzas P, Arroya-Espliguero R, Jenny M, Consuegra-Sanchez L, Kask, JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009;16:4644-53.
27. De Rosa S, Cirillo P, Pacileo M, et al. Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology. Curr Vasc Pharmacol 2011;9:188-99.
28. Liu C, Xie G, Huang W, Yang Y, Li P, Tu Z. Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and high LDL-C levels in CHD patients. J Atheroscler Thromb 2012;19:435-43.
29. Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis 2010;21:129-36.
30. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. Cardiovasc Imaging 2009;2:1093-9.
31. Kuo HK, Snih SA, Kuo YF, Raji MA. Chronic inflammation, albuminuria, and functional disability in older adults with cardiovascular disease: The national Health and Nutrition Examination Survey, 1999-2008. Atherosclerosis 2012;222:502-8.
32. Salonen I, Huttunen K, Hirvonen MR, et al. Serum myeloperoxidase is independent of the risk factors of atherosclerosis. Coronary Artery Dis 2012;23:251-8.
33. Tretjakovs P, Jurka A, Bormane I, et al. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clin Chim Acta 2012;413:25-9.
34. Mascarenhas-Melo F, Marado D, Palavra F, et al. Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc Diabetol 2013;12:61-75.
35. Collier B, Dossett LA, May AK, Diaz JJ. Glucose Control and the Inflammatory Response. Nutr Clin Pract 2008;23:3-14.
36. Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts 2012;3:345-64.
37. Tedqui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
38. King NJC, Thomas SR. Molecules in focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007;39:2167-72. (Pubitemid 47484274)
39. Petrovaara M, Raitala A, Juonala M, et al. Indoleamine 2,3-dioxigenase enzyme activity correlates with risk factors for atherosclerosis: the cardiovascular risk in Young Finns Study. Clin Exp Immunol 2007;148:106-11. (Pubitemid 46364993)
40. Niinisalo P, Raitala A, Petrovaara M, et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: The Health 2000 Study. Scand J Clin Lab Invest 2008;68:767-70.
41. Elovainio M, Hurme M, Jokela M, et al. Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: Evidence from the Young Finns study. J Affective Dis 2011;133:611-4.
42. Pedersen ER, Midttun O, Ueland PM, et al. Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31:698-704.